NASDAQ:CSBR - Champions Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.2476 -2.16 (-17.41 %) (As of 11/19/2018 02:31 PM ET)Previous Close$12.41Today's Range$10.05 - $12.2952-Week Range$3.05 - $17.90Volume88,306 shsAverage Volume121,420 shsMarket Capitalization$138.55 millionP/E Ratio-73.20Dividend YieldN/ABeta0.57 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. Receive CSBR News and Ratings via Email Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CSBR Previous Symbol CUSIPN/A Webwww.championsoncology.com Phone201-808-8400 Debt Debt-to-Equity Ratio0.23 Current Ratio0.73 Quick Ratio0.73 Price-To-Earnings Trailing P/E Ratio-73.20 Forward P/E Ratio60.28 P/E GrowthN/A Sales & Book Value Annual Sales$20.24 million Price / Sales5.65 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)($0.14) Net Income$-1,470,000.00 Net Margins-1.63% Return on Equity-97.02% Return on Assets-4.66% Miscellaneous Employees92 Outstanding Shares11,160,000Market Cap$138.55 million OptionableNot Optionable Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions What is Champions Oncology's stock symbol? Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR." How were Champions Oncology's earnings last quarter? Champions Oncology Inc (NASDAQ:CSBR) posted its quarterly earnings data on Thursday, September, 13th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.03. The biotechnology company earned $6.23 million during the quarter, compared to the consensus estimate of $5.85 million. Champions Oncology had a negative return on equity of 97.02% and a negative net margin of 1.63%. View Champions Oncology's Earnings History. When is Champions Oncology's next earnings date? Champions Oncology is scheduled to release their next quarterly earnings announcement on Thursday, December 6th 2018. View Earnings Estimates for Champions Oncology. What price target have analysts set for CSBR? 3 equities research analysts have issued 12 month price targets for Champions Oncology's shares. Their predictions range from $10.00 to $12.00. On average, they anticipate Champions Oncology's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Price Targets for Champions Oncology. What is the consensus analysts' recommendation for Champions Oncology? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Champions Oncology. Has Champions Oncology been receiving favorable news coverage? Press coverage about CSBR stock has been trending very positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Champions Oncology earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of Champions Oncology's key competitors? Some companies that are related to Champions Oncology include NanoString Technologies (NSTG), Adaptimmune Therapeutics (ADAP), Scholar Rock (SRRK), Mesoblast (MESO), Replimune Group (REPL), PDL BioPharma (PDLI), Nightstar Therapeutics (NITE), La Jolla Pharmaceutical (LJPC), Voyager Therapeutics (VYGR), CASI Pharmaceuticals (CASI), MeiraGTx (MGTX), Cellular Biomedicine Group (CBMG), LogicBio Therapeutics (LOGC), Translate Bio (TBIO) and Krystal Biotech (KRYS). Who are Champions Oncology's key executives? Champions Oncology's management team includes the folowing people: Ronnie Morris, Chief Executive Officer & DirectorDavid Barry Miller, CFO & Principal Accounting OfficerAngela M. Davies, Chief Medical OfficerMark Weinstein, Chief Information OfficerNeal Goodwin, Vice President-Research Development Who are Champions Oncology's major shareholders? Champions Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.38%), Perkins Capital Management Inc. (1.62%), EAM Investors LLC (1.61%), Ingalls & Snyder LLC (1.42%), JPMorgan Chase & Co. (1.11%) and JPMorgan Chase & Co. (1.11%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology. Which institutional investors are selling Champions Oncology stock? CSBR stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P. and Essex Investment Management Co. LLC. Company insiders that have sold Champions Oncology company stock in the last year include Daniel Newman Mendelson and Joel Ackerman. View Insider Buying and Selling for Champions Oncology. Which institutional investors are buying Champions Oncology stock? CSBR stock was acquired by a variety of institutional investors in the last quarter, including EAM Investors LLC, Renaissance Technologies LLC, Ingalls & Snyder LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., BlackRock Inc., EAM Global Investors LLC and Perkins Capital Management Inc.. View Insider Buying and Selling for Champions Oncology. How do I buy shares of Champions Oncology? Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Champions Oncology's stock price today? One share of CSBR stock can currently be purchased for approximately $10.2476. How big of a company is Champions Oncology? Champions Oncology has a market capitalization of $138.55 million and generates $20.24 million in revenue each year. The biotechnology company earns $-1,470,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Champions Oncology employs 92 workers across the globe. What is Champions Oncology's official website? The official website for Champions Oncology is http://www.championsoncology.com. How can I contact Champions Oncology? Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected] MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 86 (Vote Outperform)Underperform Votes: 110 (Vote Underperform)Total Votes: 196MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: Can individual investors take part in an IPO?